News

Pre-announcement ERDERA Clinical Trial Call 2026

Published on | 1 month ago

Programmes
Health
The European Rare Diseases Research Alliance (ERDERA) will launch a Clinical Trial Call 2026 (ECTC) on 1 July 2026, supporting multinational, Good Clinical Practice (GCP)-compliant Phase I, Phase I/II and Phase II interventional clinical trials in rare diseases.

Priority areas: paediatric rare diseases; rapidly progressive rare diseases; and rare diseases with no approved therapeutic options or with substantial residual unmet medical need despite existing treatments.

How it works: A multi‑stage process with a mandatory Expression of Interest. 
  • Stage 0 – Expression of Interest: Deadline 10 September 2026
  • Stage 1 – Short Proposal Stage: Deadline 29 October 2026
  • Stage 2 – Support Stage: January – July 2027
  • Stage 3 – Full Proposal Stage: July – September 2027
  • Funding Decisions: February 2028


An information webinar for prospective applicants will be held on 6 July 2026 and will provide an overview of the call objectives, eligibility requirements, evaluation process and indicative timeline.

More information in the pre-announcement and on the ERDERA website (incl. draft Call text). 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1961 articles available search in articles 

Testimonial

SAPHIRe - Securing the Adoption of Personalised Medicin in Regions

The Department of Economy, Science and Innovation of the Flemish government coordinates the Horizon 2020 Coordination and Support Action SAPHIRe, which started on 1 December 2018. The aim of the project is to secure the adoption of personalised medicine in all European regions, including sparsely populated and remote regions and regions with different innovation capacities. 

The activities of SAPHIRe are complementary to the smart specialisation partnership on personalised medicine – S3P4PM, which is also coordinated by the Department of Economy, Science and Innovation.